What they were paid
Kiniksa Pharmaceuticals International Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $70,000 | $81,479 | $0 | $0 | $466,630 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kiniksa Pharmaceuticals International, plc DEF 14A filed April 16, 2026, accession 0001104659-26-044410, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Kiniksa Pharmaceuticals International pays directors a $125,000 cash retainer and $250,000 in RSUs.
Committees
FY2025 · as the proxy prints themScience (Chair)
The rest of the Kiniksa Pharmaceuticals International board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Barry D. Quart | Independent Director | $414,640 |
| Felix J. Baker | Lead Independent Director | $175,478 |
| G. Bradley Cole | Independent Director | $396,640 |
| Kimberly J. Popovits | Independent Director | $406,640 |
| M. Cantey Boyd | Independent Director | $140,479 |
| Sanj K. Patel | Chair of the Board | $0 |
| Stephen R. Biggar | Independent Director | $150,478 |
| Thomas R. Malley | Independent Director | $411,640 |
| Tracey L. McCain | Independent Director | $396,640 |
The full Kiniksa Pharmaceuticals International compensation record
free company briefThis page is one director within Kiniksa Pharmaceuticals International's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat